NEW PUBLISHED ARTICLE: Zalcman et al., 2024

Congratulations to Dr. Brosseau, Dr Zalcman, and colleagues on the publication of their article “YAP/TEAD involvement in resistance to paclitaxel chemotherapy in lung cancer” in the 𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑎𝑛𝑑 𝐶𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝐵𝑖𝑜𝑐ℎ𝑒𝑚𝑖𝑠𝑡𝑟𝑦 journal. We are delighted to have contributed to the success of this article!

The Yes-associated protein (YAP) oncoprotein is linked to metastasis and chemotherapy resistance in lung cancer cells. This study explored the effects of inhibiting 𝐘𝐀𝐏 𝐮𝐬𝐢𝐧𝐠 𝐘𝐀𝐏/𝐓𝐄𝐀 𝐝𝐨𝐦𝐚𝐢𝐧 (𝐓𝐄𝐀𝐃) 𝐭𝐫𝐚𝐧𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 𝐟𝐚𝐜𝐭𝐨𝐫 𝐢𝐧𝐭𝐞𝐫𝐚𝐜𝐭𝐢𝐨𝐧 inhibitors in chemo-resistant lung cancer cells.

The authors examined YAP activation, cell migration, and TEAD transcriptional activity in 𝐜𝐚𝐧𝐜𝐞𝐫 𝐜𝐞𝐥𝐥 𝐥𝐢𝐧𝐞𝐬 with elevated YAP levels. They analyzed parental (A549) and paclitaxel resistant (A549R) cell lines. A 𝟑𝐃 𝐦𝐢𝐜𝐫𝐨𝐟𝐥𝐮𝐢𝐝𝐢𝐜 𝐜𝐮𝐥𝐭𝐮𝐫𝐞 𝐝𝐞𝐯𝐢𝐜𝐞 was used to study a YAP/TEAD inhibitor (IV#6)/paclitaxel combination's effect on cells from fresh lung cancer samples.

Results showed 𝐡𝐢𝐠𝐡𝐞𝐫 𝐘𝐀𝐏 𝐚𝐜𝐭𝐢𝐯𝐢𝐭𝐲 in resistant cells, with YAP/TEAD inhibitors reducing YAP activity and cell motility. 𝐂𝐨𝐦𝐛𝐢𝐧𝐢𝐧𝐠 𝐘𝐀𝐏 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐭𝐫𝐚𝐦𝐞𝐭𝐢𝐧𝐢𝐛 𝐨𝐫 𝐩𝐚𝐜𝐥𝐢𝐭𝐚𝐱𝐞𝐥 sensitized resistant cells and 𝐤𝐢𝐥𝐥𝐞𝐝 𝐜𝐚𝐧𝐜𝐞𝐫 𝐜𝐞𝐥𝐥𝐬 in a 3D system. This study highlights the potential of targeting YAP/TEAD to overcome chemotherapy resistance. The article is already available on the journal's website! 𝐃𝐎𝐈: 𝐡𝐭𝐭𝐩:/𝐝𝐨𝐢.𝐨𝐫𝐠/𝟏𝟎.𝟏𝟎𝟎𝟕/𝐬𝟏𝟏𝟎𝟏𝟎-𝟎𝟐𝟒-𝟎𝟒𝟗𝟒𝟗-𝟕